Log In
BCIQ
Print this Print this
 

crenezumab (MABT5102A, RG7412)

Also known as: Anti-Abeta

  Manage Alerts
Collapse Summary General Information
Company AC Immune S.A.
DescriptionHumanized mAb against beta amyloid
Molecular Target Beta amyloid
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat mild to moderate Alzheimer's disease (AD); Treat prodromal to mild Alzheimer's disease (AD)
Regulatory Designation
PartnerGenentech Inc.;
Roche

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today